PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,976 stories, page 782 of 783

Advanced search
🇩🇪Devicescorporate.hartmann.infoTier 1 · Company source

HARTMANN by number

Paul Hartmann AGOriginal source
🇩🇪Devicescorporate.hartmann.infoTier 1 · Company source

HARTMANN's healthcare innovations

Paul Hartmann AGOriginal source
🇮🇱Industrycgen.comTier 1 · Company source

Compugen - From Code to Cure®

CompugenOriginal source
🇮🇱Industrycgen.comTier 1 · Company source

RILVEGOSTOMIG/Fc reduced anti-PD1/TIGIT bispecific antibody opens in new window

CompugenOriginal source
🇮🇱Industrycgen.comTier 1 · Company source

GS-0321 opens in new window

CompugenOriginal source
🇮🇱Industrycgen.comTier 1 · Company source

COM902/high affinity Fc reduced anti-TIGIT antibody opens in new window

CompugenOriginal source
🇮🇱Industrycgen.comTier 1 · Company source

COM701/COM902/Pembrolizumab Triple Combination opens in new window

CompugenOriginal source
🌍Industrycamp.comTier 1 · Company source

Visit the Slime Bar at CAMP

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Things To Do At CAMP Washington D.C. | CAMP

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Washington D.C.

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Meet & Greet Party With Bluey! at CAMP Washington D.C.

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

CAMP Washington D.C. | A Family Experience Store

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Press and Partnerships

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Philadelphia

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP New York City

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Miami

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Meet & Greets at CAMP!

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Los Angeles

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Gabby's Dollhouse at CAMP Los Angeles

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Chicago

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Charlotte

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Gabby's Dollhouse at CAMP Charlotte

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Birthday Parties at CAMP | Book a Party Near You

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Boston

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

Slime Bar at CAMP Atlanta

CAMP4 TherapeuticsOriginal source
🌍Industrycamp.comTier 1 · Company source

CAMP | Immersive Kids Activities, Slime, Crafts & Birthday Parties

CAMP4 TherapeuticsOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

What Are Stem Cells? | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Introduction to Hippocampal Neurons | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Primary Neurons and Glial Cells | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Primary Immune Cells and Media | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

| Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

PBMCs for translational immune research | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

MycoAlert® Mycoplasma Detection | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Mycoplasma contamination of cell cultures | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Cortical Neurons | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Introduction to Astroglia | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Hematopoietic Stem Cell Therapy | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Endothelial Primary Cells | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

CellBio Services | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Cell Culture Techniques | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Cell Assays and Analysis | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Cell and Gene Therapy | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

CD34+ Positive Cells | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Culture Media and Reagents | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

An Introduction to Primary Cell Culture | Lonza

Lonza BioscienceOriginal source
🇨🇭Industrybioscience.lonza.comTier 3 · Secondary coverage

Airway Cells and Media | Lonza

Lonza BioscienceOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

Israel Elias Garcia, MSN discuses the benefits of CyPath® Lung – bioAffinity

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

“Not every single nodule needs a biopsy…” Sai Karan “Vamsi” Guda, DO – bioAffinity

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

“Lung cancer can happen anywhere, and the trick is finding it sooner than later.” Gregory White, MD – bioAffinity

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

“I needed a real-time test…that could tell me there is a tumor cell.” Gordon Downie, MD, PhD

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

“I can sleep at night and not worry that maybe I’m missing a malignancy…” Daya Nadarajah, MD – bioAffinity

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

Negative CyPath® Lung Test Result Prevented Biopsy – bioAffinity

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

Positive CyPath® Lung Test Result Led to Diagnosis of Lung Cancer at Earliest Stage 1A – bioAffinity

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 – bioAffinity

bioAffinity TechnologiesOriginal source
🌍Industrybioaffinitytech.comTier 1 · Company source

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month – bioAffinity

bioAffinity TechnologiesOriginal source
🇺🇸Industrybilliontoone.comTier 1 · Company source

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions - BillionToOne

BillionToOneOriginal source
🇺🇸Industrybilliontoone.comTier 1 · Company source

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds - BillionToOne

BillionToOneOriginal source
🇺🇸Industrybilliontoone.comTier 1 · Company source

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 - BillionToOne

BillionToOneOriginal source
🇺🇸Industrybilliontoone.comTier 1 · Company source

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026 - BillionToOne

BillionToOneOriginal source